We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
Vols saber com serà la teva estada a l’Hospital Universitari Vall d’Hebron? Aquí trobaràs tota la informació.
On the left neurons treated with the secretoma of unstimulated astrocytes and on the right neurons treated with astrocytes previously exposed to patients with high inflammatory activity
The research led by Vall d'Hebron is a breakthrough in the search for specific and effective treatments for the disease.
A research led by the Clinical Neuroimmunology group of the Vall d'Hebron Research Institute (VHIR) and the Multiple Sclerosis Center of Catalonia (Cemcat) has identified one of the mechanisms that cause neuronal damage in patients with multiple sclerosis (MS). The study published in Clinical and Translational Medicine has shown that inflammation at the onset of the disease causes a change in astrocytes, a type of star-shaped cell of the central nervous system. The affected astrocytes trigger a reaction of the neurons that causes alterations typically observed in this pathology.
The aim of the study was to investigate the effect of inflammation on astrocytes to determine whether they trigger the neuronal damage observed in patients. First, "pure" astrocytes (from healthy mice) were acquired and placed in contact with cerebrospinal fluid. Three groups were made: one with fluid from patients with very active MS and high inflammation; the second with patients with low activity; and finally, with patients with headache unrelated to MS. The secretome, the set of proteins released by a particular organism, from the resulting astrocytes was put into a culture of healthy neurons to study its effect. Neurons treated with the secretome from astrocytes that had been in cerebrospinal fluid from patients with very active multiple sclerosis showed clear signs of neurodegeneration like reduced neuronal complexity and synaptic plasticity. This result was much reduced in mild patients and not visible in those without the disease.
"It was important to have patients without MS to ensure that it was a specific mechanism of this pathology", explains Dr. Clara Matute, researcher of the Clinical Neuroimmunology group at VHIR and Cemcat, who has led the research. She also wants to highlight that "the cerebrospinal fluid was extracted from patients during their first outbreak, so we know that this mechanism is active already in the early stages of the disease".
The first step towards targeted and effective treatments
Once established the causality between the change in astrocyte status and neuronal damage, the next step was to analyze the molecular composition of cells that had been in contact with cerebrospinal fluid from patients with high inflammation. About thirty altered factors were identified, most of them related to NF-kB signaling. NF-kB regulates the body's immune and inflammatory responses. The scientists tried to identify the specific molecules of the NF-kB pathway that trigger the observed reaction, CHI3L1 and SerpinE1 were proposed but further studies are needed to confirm this.
As Dr. Manuel Comabella, principal investigator of the Clinical Neuroimmunology group at VHIR and head of the laboratory at Cemcat, explains, "identifying the biomarkers and proteins that cause neuronal damage is the first step to design more effective and specific treatments, limiting side effects as much as possible. The ultimate goal is to improve our patients' quality of life". Without this first step, the road to a new drug is much more challenging. In short, this study has begun to sketch a map where before there was an empty space between the disease and the lesions caused by it. Scientists now intuit the pathways by which this damage occurs and thus the process of finding treatment strategies, slowing or even reversing the progression of the disease has been simplified. The more detailed this map is, the easier it will be for researchers to find new solutions.
“Identifying the biomarkers and proteins that cause neuronal damage is the first step to design more effective and specific treatments"
Select the newsletter you want to receive:
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.